Targeted hope: redefining treatment for pancreatic cancer | UoW

Pancreatic cancer remains one of the deadliest cancers, with survival rates below 10 per cent and treatments often as harsh as the disease itself. PhD researcher Elahe Minaei, under the supervision of Associate Professor Kara Vine-Perrow, is changing that story.

Elahe has developed biodegradable micro-implants that deliver chemotherapy and immunotherapy directly into tumours, targeting treatment at the source. This innovation reduces toxic side effects, activates the immune system, and makes powerful therapies safer and more effective.

Her preclinical studies show highly promising results, with industry partners calling the approach a “game changer” and clinicians hopeful it could finally make immunotherapy effective for pancreatic cancer.

Driven by compassion for patients and their families, Elahe’s research offers hope for longer, better lives - positioning Australia as a global leader in next-generation cancer care.

Entrant: Elahe Minaei, Associate Professor Kara Vine-Perrow